MedinCell begins first Covid-19 clinical study with Ivermectin
This article was originally published here
The randomised, double-blind, exploratory phase I trial A has been designed to evaluate the pharmacokinetic profile, safety and tolerability of a continuous daily dosing regimen of Ivermectin in
The post MedinCell begins first Covid-19 clinical study with Ivermectin appeared first on Pharmaceutical Business review.
Leave a Reply
Want to join the discussion?Feel free to contribute!